Fig. 1
From: RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study
Anti-Tumor Activity of RAF2 inhibitor with rechallenge after RAF1 inhibitor. Illustration depicting the Anti-Tumor Activity of RAF2 inhibitor upon rechallenge subsequent to RAF1 inhibitor treatment. The figure visually captures the treatment response dynamics, showcasing the impact of RAF2 inhibitor rechallenge on tumor progression following initial RAF1 inhibitor therapy. CR = Complete Response; PR = Partial Response; ORR = Overall Response Rate; SD = Stable Disease; PD = Progressive Disease; DCR = Disease Control Rate; CBR = Clinical Benefit Rate; RAF1i = First RAF inhibitor; RAF2i = Second RAF inhibitor